Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ATNF

ATNF - 180 Life Sciences Corp. Stock Price, Fair Value and News

2.18USD-0.21 (-8.79%)Market Closed

Market Summary

ATNF
USD2.18-0.21
Market Closed
-8.79%

ATNF Stock Price

View Fullscreen

ATNF RSI Chart

ATNF Valuation

Market Cap

2.1M

Price/Earnings (Trailing)

-0.13

Price/Sales (Trailing)

70.4

EV/EBITDA

-0.07

Price/Free Cashflow

-0.25

ATNF Price/Sales (Trailing)

ATNF Profitability

EBT Margin

-71657.26%

Return on Equity

1.7K%

Return on Assets

-471.94%

Free Cashflow Yield

-393.91%

ATNF Fundamentals

ATNF Revenue

Revenue (TTM)

25.9K

ATNF Earnings

Earnings (TTM)

-16.2M

Earnings Growth (Yr)

77.54%

Earnings Growth (Qtr)

12.82%

Breaking Down ATNF Revenue

Last 7 days

2.4%

Last 30 days

32.9%

Last 90 days

19.8%

Trailing 12 Months

107.6%

How does ATNF drawdown profile look like?

ATNF Financial Health

Current Ratio

0.45

ATNF Investor Care

Shares Dilution (1Y)

236.43%

Diluted EPS (TTM)

-29.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20220000
20210000
20200000
201900025.9K
20170000

Tracking the Latest Insider Buys and Sells of 180 Life Sciences Corp.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 28, 2023
feldmann marc
acquired
-
-
135,377
-
Dec 15, 2023
feldmann marc
sold
-4,700
0.188
-25,000
-
Dec 15, 2023
woody james n.
bought
4,700
0.188
25,000
chief executive officer
Sep 04, 2023
ray russell t
acquired
29,178
1.36
21,455
-
Sep 04, 2023
mcgovern jr. donald a.
acquired
-
-
25,186
-
Sep 04, 2023
marrone pamela g
acquired
-
-
22,388
-
Sep 04, 2023
gold lawrence marshall
acquired
-
-
21,455
-
Jun 01, 2023
steinman lawrence
bought
22,068
1.226
18,000
-
May 31, 2023
mcgovern jr. donald a.
bought
11,470
1.147
10,000
-
May 19, 2023
mcgovern jr. donald a.
bought
5,800
1.16
5,000
-

1–10 of 50

Which funds bought or sold ATNF recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
new
-
-
-
-%
May 20, 2024
Virtu Financial LLC
sold off
-100
-16,000
-
-%
May 16, 2024
Semmax Financial Advisors Inc.
sold off
-100
-1.00
-
-%
May 16, 2024
Semmax Financial Advisors Inc.
new
-
3.00
3.00
-%
May 15, 2024
CITADEL ADVISORS LLC
sold off
-100
-13,871
-
-%
May 15, 2024
MORGAN STANLEY
sold off
-100
-55.00
-
-%
May 15, 2024
Tower Research Capital LLC (TRC)
sold off
-100
-2,094
-
-%
May 15, 2024
Tower Research Capital LLC (TRC)
new
-
8,022
8,022
-%
May 15, 2024
MSD Partners, L.P.
sold off
-100
-378
-
-%
May 15, 2024
TWO SIGMA SECURITIES, LLC
added
1,669
134
299
-%

1–10 of 35

Are Funds Buying or Selling ATNF?

Are funds buying ATNF calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ATNF
No. of Funds

Unveiling 180 Life Sciences Corp.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
9.99%
1,112,480
SC 13G
Apr 14, 2023
feldmann marc
3.4%
141,747
SC 13D/A
Feb 09, 2022
vanguard index funds
2.95%
1,004,406
SC 13G/A
Feb 09, 2022
vanguard group inc
2.95%
1,004,406
SC 13G/A
Feb 07, 2022
nanchahal jagdeep
4.5%
1,520,564
SC 13G/A
Dec 13, 2021
feldmann marc
8.2%
2,834,930
SC 13D/A
Feb 10, 2021
vanguard group inc
6.54%
1,179,639
SC 13G
Feb 08, 2021
vanguard index funds
5.93%
1,069,400
SC 13G
Dec 31, 2020
bauer ronald
9.2%
2,280,171
SC 13G
Dec 30, 2020
kbl iv sponsor llc
9.03%
2,223,365
SC 13D/A

Recent SEC filings of 180 Life Sciences Corp.

View All Filings
Date Filed Form Type Document
Jul 19, 2024
S-1
Initial Public Offering
Jul 02, 2024
8-K
Current Report
May 21, 2024
8-K
Current Report
May 15, 2024
8-K
Current Report
May 15, 2024
10-Q
Quarterly Report
May 09, 2024
8-K
Current Report
Apr 29, 2024
10-K/A
Annual Report
Apr 24, 2024
EFFECT
EFFECT
Apr 24, 2024
EFFECT
EFFECT
Apr 22, 2024
POS AM
POS AM

Peers (Alternatives to 180 Life Sciences Corp.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

180 Life Sciences Corp. News

Latest updates
Defense World17 Jul 202412:29 pm
Investing.com02 Jul 202407:00 am

180 Life Sciences Corp. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q42022Q32022Q22021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42017Q2
Revenue------------------55,729
Operating Expenses-58.9%1,452,4883,538,1873,682,9804,803,8455,639,896---4,462,0554,217,4764,013,1692,948,3032,415,973731,078934,1991,566,862--
  S&GA Expenses-100.0%-2,433,1932,762,0764,008,8525,053,855---2,490,0513,519,6052,678,2312,542,231-2,751,3611,786,1223,513,039995,3284,820,828-
  R&D Expenses-100.0%-972,113789,441216,684503,360---324,668316,473246,61399,899--351,005472,862--
EBITDA Margin49.1%-857-1,684-2,026-1,771-1,527-612920-96.51-777-1,102-1,836-915-381-----
Interest Expenses-13.8%10,03211,63411,60611,5568,339---55,5745,45512,246112,933594,02082,990172,498152,916--
Income Taxes99.8%-4,389-2,345,025-------6,617-5,612-5,571-5,404-5,253-5,135-4,936-5,102-227,079-
Earnings Before Taxes90.2%-1,231,494-12,610,785-3,680,169-4,762,078-22,685,027---1,029,60018,291,244-23,464,707-16,203,989-7,946,016-834,553262,446-2,386,362-25,820,100-
EBT Margin49.1%-858-1,685-2,027-1,772-1,528-614918-99.44-784-1,130-1,867-952-420-----
Net Income88.0%-1,227,105-10,265,760-3,680,169-4,762,078-21,742,278---1,036,21718,296,856-23,459,136-16,198,585-7,940,763-829,418267,383-2,381,260-25,593,021-
Net Income Margin50.7%-768-1,559-1,991-1,736-1,492-614918-98.76-783-1,129-1,866-952-419-----
Free Cashflow-21.7%-2,160,014-1,775,475-3,116,843-3,869,891-2,926,755-3,596,366-3,531,533-2,072,931-5,027,530-4,002,668-4,011,185-6,330,045-3,216,392-----
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-34.6%3,4425,2594,95813,66714,92219,65034,33653,35859,67762,71465,07056,26560,11255,53311,02412,62612,36851,88451,57350,23766,471
  Current Assets-49.0%1,8553,6403,3712,9344,1968,9286,5154,6478,95711,20113,6344,0468,2984,0157211,186388748901209145
    Cash Equivalents-65.8%6761,9762,6632,0092,6466,9703,5891,6255,6698,22511,6881,8366,0532,10933.0070.0098.0083.00836110135
  Goodwill------9,06312,29112,41112,53036,98836,89637,56137,18336,901---36,423---
Liabilities-18.4%4,3965,3875,1076,9517,7838,3068,26110,56618,77323,39127,92953,54937,40325,2476,2774,1427,23813,3146,8135,4565,203
  Current Liabilities-19.4%4,0805,0634,8074,2735,1225,6584,7256,96615,07719,69924,22549,79933,62221,4216,2774,1423,2139,6412,7881,4311,178
Shareholder's Equity-647.2%-954-127-6,7167,14011,34426,07542,79140,90539,32337,1412,71622,70930,28735,46735,88234,74738,5715,0005,0005,000
  Retained Earnings-0.8%-128,413-127,343-126,116-115,850-112,170-107,408-85,666-64,179-67,118-68,682-69,718-88,015-64,556-48,357-7,933-4,583852-37,4731,3601,3821,393
  Additional Paid-In Capital0.2%130,354130,117128,815125,466122,195121,638115,427108,786107,930107,187106,15489,49686,43678,00512,6809,5834,14775,8903,6393,6183,607
Shares Outstanding59.5%85353535519719719794.0090.0090.0090.0086.0083.0074.0069.00-------
Float----5,851-25,377-25,377-271,883-20,792-------50,159-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations52.2%-1,033-2,160-1,775-3,116-3,869-2,926-3,596-3,531-2,072-5,027-4,002-4,011-6,330-3,216-53.97-192-409-2,158-216-636-307
  Share Based Compensation-236---557---------1,506-------
Cashflow From Investing--------------12,878973707-66.86-69,979-38816,65453,005
Cashflow From Financing-118.0%-2641,4682,4472,462-4696,3965,488-494-5151,54913,729-22810,363-9,22514712.00333-38,9621,330-16,041-52,834
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ATNF Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating Expenses:  
Research and development$ 365,186$ 578,309
Research and development - related parties170,542216,684
General and administrative1,556,7404,008,852
Total Operating Expenses2,092,4684,803,845
Loss From Operations(2,092,468)(4,803,845)
Other (Expense) Income:  
Other income1,039,364 
Interest expense(16,449)(11,556)
Change in fair value of derivative liabilities(191)53,323
Total Other (Expense) Income, Net1,022,72441,767
Loss Before Income Taxes(1,069,744)(4,762,078)
Income tax benefit
Net Loss(1,069,744)(4,762,078)
Other Comprehensive Income (Loss):  
Foreign currency translation adjustments6,460663
Total Comprehensive Loss$ (1,063,284)$ (4,761,415)
Basic and Diluted Net Loss per Common Share  
Basic (in Dollars per share)$ (1.68)$ (24.15)
Diluted (in Dollars per share)$ (1.68)$ (24.15)
Weighted Average Number of Common Shares Outstanding:  
Basic (in Shares)638,339197,219
Diluted (in Shares)638,339197,219

ATNF Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Assets  
Cash$ 675,977$ 1,975,799
Prepaid expenses and other current assets1,178,9711,664,107
Total Current Assets1,854,9483,639,906
Intangible assets, net1,586,7921,619,570
Total Assets3,441,7405,259,476
Liabilities and Stockholders’ Deficit  
Accounts payable1,784,1501,892,611
Accrued expenses1,416,7901,869,814
Loans payable - current portion772,3341,034,124
Derivative liabilities24958
Total Current Liabilities4,080,3075,062,616
Loans payable - noncurrent portion16,54419,936
Deferred tax liability299,355304,657
Total Liabilities4,396,2065,387,209
Commitments and contingencies (Note 8)
Stockholders’ Deficit:  
Preferred stock value
Common stock, $0.0001 par value; 100,000,000 shares authorized; 852,772 and 534,719 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively8654
Additional paid-in capital130,353,728130,117,209
Accumulated other comprehensive income(2,894,879)(2,901,339)
Accumulated deficit(128,413,401)(127,343,657)
Total Stockholders’ Deficit(954,466)(127,733)
Total Liabilities and Stockholders’ Deficit3,441,7405,259,476
Related Party  
Liabilities and Stockholders’ Deficit  
Accounts payable – related parties53,076266,009
Accrued expenses - related parties53,708
Class C Preferred Stock  
Stockholders’ Deficit:  
Preferred stock value
Class K Preferred Stock  
Stockholders’ Deficit:  
Preferred stock value
ATNF
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
 CEO
 WEBSITEhttps://180lifesciences.com
 INDUSTRYBiotechnology
 EMPLOYEES5

180 Life Sciences Corp. Frequently Asked Questions


What is the ticker symbol for 180 Life Sciences Corp.? What does ATNF stand for in stocks?

ATNF is the stock ticker symbol of 180 Life Sciences Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 180 Life Sciences Corp. (ATNF)?

As of Fri Jul 19 2024, market cap of 180 Life Sciences Corp. is 2.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATNF stock?

You can check ATNF's fair value in chart for subscribers.

What is the fair value of ATNF stock?

You can check ATNF's fair value in chart for subscribers. The fair value of 180 Life Sciences Corp. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 180 Life Sciences Corp. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATNF so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 180 Life Sciences Corp. a good stock to buy?

The fair value guage provides a quick view whether ATNF is over valued or under valued. Whether 180 Life Sciences Corp. is cheap or expensive depends on the assumptions which impact 180 Life Sciences Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATNF.

What is 180 Life Sciences Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, ATNF's PE ratio (Price to Earnings) is -0.13 and Price to Sales (PS) ratio is 70.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATNF PE ratio will change depending on the future growth rate expectations of investors.